SINTA

0.0

Impact

Scholar

6

H-Index

Journal of Chemical Learning Innovation

an Open Access Journal

Development of Pyrimidinon Derivative Compounds from Methoxy Bis-Chalcone Analogs as Potential Anticancer Candidates

Nia Tussholiha
Airlangga University ROR
Indonesia
nialihaa93@gmail.com
Share

  • Purpose of the study: This study aims to evaluate its bioactivity as a candidate anticancer compound through inhibition testing of dihydrofolate reductase enzyme activity.

    Methodology: Organic synthesis methods through condensation and cyclization, reflux, recrystallization, preparative thin layer chromatography, Fisher John Melting Point Apparatus, ultraviolet visible spectrometer, nuclear magnetic resonance spectrometer, mass spectrometer, infrared spectrometer, centrifugation, in vitro dihydrofolate reductase enzyme inhibition test, probit analysis, methotrexate as a positive control, and evaluation of anticancer bioactivity.

    Main Findings: The pyrimidinone derivative compound was successfully synthesized and confirmed through physical and spectroscopic characterization. The test results showed significant inhibitory activity against the dihydrofolate reductase enzyme. The synthesized compound had a fifty percent inhibitory concentration of 25.086 micrograms per milliliter, lower than the positive control, indicating better anticancer potential and high inhibitory effectiveness.

    Novelty/Originality of this study: The novelty of this research lies in the synthesis of pyrimidinone derivatives based on bis-chalcone analogs containing methoxy groups, which have not been widely studied as anticancer candidates. This study provides new insights into the relationship between structure and biological activity, while also expanding the development of heterocyclic compounds as dihydrofolate reductase inhibitors for anticancer therapy.

  • How to cite

    [1]
    N. Tussholiha, “Development of Pyrimidinon Derivative Compounds from Methoxy Bis-Chalcone Analogs as Potential Anticancer Candidates”, Jor. Chem. Lea. Inn, vol. 3, no. 1, pp. 100–107, May 2026, doi: 10.37251/jocli.v3i1.3170.

    More Citation Formats

  • 43
    Abstract views
    31
    Downloads

    Metrics — Badges

    1. M. S. Ghufran, P. Soni, and G. R. Duddukuri, “The Global Concern for Cancer Emergence and Its Prevention: A Systematic Unveiling of the Present Scenario,” in Bioprospecting of Tropical Medicinal Plants, Cham: Springer Nature Switzerland, 2023, pp. 1429–1455. doi: 10.1007/978-3-031-28780-0_60. DOI: https://doi.org/10.1007/978-3-031-28780-0_60
    2. J. Zhou, W. Yang, and Q. Liu, “Cancer challenges worldwide and in China: preparing for the inevitable,” Sci. China Life Sci., vol. 65, no. 2, pp. 442–444, 2022, doi: 10.1007/s11427-021-2009-0. DOI: https://doi.org/10.1007/s11427-021-2009-0
    3. H. Bahrami and M. Tafrihi, “Global trends of cancer: The role of diet, lifestyle, and environmental factors,” Cancer Innov., vol. 2, no. 4, pp. 290–301, Aug. 2023, doi: 10.1002/cai2.76. DOI: https://doi.org/10.1002/cai2.76
    4. S. Farina, A. Sabatelli, S. Boccia, and G. Scambia, “Environment, lifestyle, and cancer in women,” Int. J. Gynecol. Obstet., vol. 171, no. S1, pp. 138–146, 2025, doi: 10.1002/ijgo.70156. DOI: https://doi.org/10.1002/ijgo.70156
    5. R. Kaur, A. Bhardwaj, and S. Gupta, “Cancer treatment therapies: traditional to modern approaches to combat cancers,” Mol. Biol. Rep., vol. 50, no. 11, pp. 9663–9676, Nov. 2023, doi: 10.1007/s11033-023-08809-3. DOI: https://doi.org/10.1007/s11033-023-08809-3
    6. P. Garg, J. Malhotra, P. Kulkarni, D. Horne, R. Salgia, and S. S. Singhal, “Emerging therapeutic strategies to overcome drug resistance in cancer cells,” Cancers (Basel)., vol. 16, no. 13, pp. 1–25, 2024, doi: 10.3390/cancers16132478. DOI: https://doi.org/10.3390/cancers16132478
    7. E. Kabir and M. Uzzaman, “A review on biological and medicinal impact of heterocyclic compounds,” Results Chem., vol. 4, no. August, pp. 1–11, 2022, doi: 10.1016/j.rechem.2022.100606. DOI: https://doi.org/10.1016/j.rechem.2022.100606
    8. J. Baranwal, S. Kushwaha, S. Singh, and A. Jyoti, “A Review on the synthesis and pharmacological activity of heterocyclic compounds,” Curr. Phys. Chem., vol. 13, no. 1, pp. 2–19, Mar. 2023, doi: 10.2174/1877946813666221021144829. DOI: https://doi.org/10.2174/1877946813666221021144829
    9. G. H. Elgemeie, R. A. Azzam, W. A. Zaghary, M. A. Khedr, and G. E. Elsherif, “Medicinal chemistry of pyrazolopyrimidine scaffolds substituted with different heterocyclic nuclei,” Curr. Pharm. Des., vol. 28, no. 41, pp. 3374–3403, Nov. 2022, doi: 10.2174/1381612829666221102162000. DOI: https://doi.org/10.2174/1381612829666221102162000
    10. A. Alsharif, M. Allahyani, A. Aljuaid, A. A. Alsaiari, M. M. Almehmadi, and M. Asif, “Diverse pharmacological potential of various substituted pyrimidine derivatives,” Curr. Org. Chem., vol. 27, no. 20, pp. 1779–1798, Nov. 2023, doi: 10.2174/0113852728266665231101112129. DOI: https://doi.org/10.2174/0113852728266665231101112129
    11. A. A. Ghoneim, A. F. El-Farargy, and R. B. Bakr, “Design, synthesis, molecular docking of novel substituted pyrimidinone derivatives as anticancer agents,” Polycycl. Aromat. Compd., vol. 42, no. 5, pp. 2538–2554, 2022, doi: 10.1080/10406638.2020.1837888. DOI: https://doi.org/10.1080/10406638.2020.1837888
    12. W. A. Zaki et al., “Design, synthesis, in vitro, and in silico studies of new N5-substituted-pyrazolo[3,4-d]pyrimidinone derivatives as anticancer CDK2 inhibitors,” Pharmaceuticals, vol. 16, no. 11, pp. 1–13, 2023, doi: 10.3390/ph16111593. DOI: https://doi.org/10.3390/ph16111593
    13. G. E. S. Chaudhry, A. Md Akim, Y. Y. Sung, and T. M. T. Sifzizul, “Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics,” Front. Pharmacol., vol. 13, no. August, pp. 1–24, 2022, doi: 10.3389/fphar.2022.842376. DOI: https://doi.org/10.3389/fphar.2022.842376
    14. Y. Zhao et al., “Cancer metabolism: The role of ROS in DNA damage and induction of Apoptosis in cancer cells,” Metabolites, vol. 13, no. 7, pp. 1–25, 2023, doi: 10.3390/metabo13070796. DOI: https://doi.org/10.3390/metabo13070796
    15. B. S. Manya et al., “Insights into the biological activities and substituent effects of pyrrole derivatives: The chemistry‐biology connection,” Chem. Biodivers., vol. 21, no. 8, pp. 1–9, Aug. 2024, doi: 10.1002/cbdv.202400534. DOI: https://doi.org/10.1002/cbdv.202400534
    16. R. M. Keshk, Z. A. Salama, S. K. Elsaedany, E. M. A. ElRehim, and D. M. Beltagy, “Synthesis, antimicrobial, anti-inflammatory, antioxidant and cytotoxicity of new pyrimidine and pyrimidopyrimidine derivatives,” Sci. Rep., vol. 15, no. 1, pp. 1–16, Mar. 2025, doi: 10.1038/s41598-025-92066-w. DOI: https://doi.org/10.1038/s41598-025-92066-w
    17. S. Chowdhary, Preeti, Shekhar, N. Gupta, R. Kumar, and V. Kumar, “Advances in chalcone-based anticancer therapy: mechanisms, preclinical advances, and future perspectives,” Expert Opin. Drug Discov., vol. 19, no. 12, pp. 1417–1437, Dec. 2024, doi: 10.1080/17460441.2024.2436908. DOI: https://doi.org/10.1080/17460441.2024.2436908
    18. T. Constantinescu and A. G. Mihis, “Two important anticancer mechanisms of natural and synthetic chalcones,” Int. J. Mol. Sci., vol. 23, no. 19, pp. 1–26, 2022, doi: 10.3390/ijms231911595. DOI: https://doi.org/10.3390/ijms231911595
    19. D. Pansare et al., “Synthesis and Biological Evaluation of Thiazoline, Thiophene and Thiazole Scaffolds,” in S-Heterocycles, Singapore: Springer Nature Singapore, 2024, pp. 105–133. doi: 10.1007/978-981-97-4308-7_3. DOI: https://doi.org/10.1007/978-981-97-4308-7_3
    20. A. Ragab, S. A. Fouad, Y. A. Ammar, D. S. Aboul-Magd, and M. S. Abusaif, “Antibiofilm and anti-quorum-sensing activities of novel pyrazole and pyrazolo[1,5-a]pyrimidine derivatives as carbonic anhydrase I and II Inhibitors: Design, synthesis, radiosterilization, and molecular Docking Studies,” Antibiotics, vol. 12, no. 1, pp. 1–39, 2023, doi: 10.3390/antibiotics12010128. DOI: https://doi.org/10.3390/antibiotics12010128
    21. S. Shah, R. Narang, V. J. Singh, G. Pilli, and S. K. Nayak, “A review on anticancer profile of flavonoids: Sources, chemistry, mechanisms, structure-activity relationship and anticancer activity,” Curr. Drug Res. Rev., vol. 15, no. 2, pp. 122–148, Jul. 2023, doi: 10.2174/2589977515666230120144852. DOI: https://doi.org/10.2174/2589977515666230120144852
    22. C. M. C. Andrés, J. M. Pérez de la Lastra, E. Bustamante Munguira, C. Andrés Juan, and E. Pérez-Lebeña, “Anticancer activity of metallodrugs and metallizing host defense peptides—current developments in structure-activity relationship,” Int. J. Mol. Sci., vol. 25, no. 13, pp. 1–45, 2024, doi: 10.3390/ijms25137314. DOI: https://doi.org/10.3390/ijms25137314
    23. D. Muhammed Aziz, S. A. Hassan, A. A. M. Amin, M. N. Abdullah, K. Qurbani, and S. B. Aziz, “A synergistic investigation of azo-thiazole derivatives incorporating thiazole moieties: a comprehensive exploration of their synthesis, characterization, computational insights, solvatochromism, and multimodal biological activity assessment,” RSC Adv., vol. 13, no. 49, pp. 34534–34555, 2023, doi: 10.1039/d3ra06469g. DOI: https://doi.org/10.1039/D3RA06469G
    24. D. Tiwari et al., “A review on natural bioactive compounds of Taraxacum officinale Weber: a potential anticancer plant,” RPS Pharm. Pharmacol. Reports, vol. 3, no. 2, pp. 1–9, Apr. 2024, doi: 10.1093/rpsppr/rqae009. DOI: https://doi.org/10.1093/rpsppr/rqae009
    25. P. Sivakumar, S. Bharanidharan, R. Rajamohan, B. Anandhan, T. Sumathi, and S. Kamatchi, “Synthesis and spectral characterization of 4-methylthiazole derivatives: DFT approach and biological activities,” New J. Chem., vol. 47, no. 34, pp. 16216–16227, 2023, doi: 10.1039/D3NJ03046F. DOI: https://doi.org/10.1039/D3NJ03046F
    26. T. Kowalska and M. Sajewicz, “Thin-layer chromatography (TLC) in the screening of botanicals–Its versatile potential and selected applications,” Molecules, vol. 27, no. 19, pp. 1–23, 2022. DOI: https://doi.org/10.3390/molecules27196607
    27. Y. Fukunaga, R. Ogawa, A. Homma, and T. Okada, “Thin layer chromatography‐freeze surface‐enhanced raman spectroscopy: A powerful tool for monitoring synthetic reactions,” Chem. – A Eur. J., vol. 29, no. 39, pp. 1–9, Jul. 2023, doi: 10.1002/chem.202300829. DOI: https://doi.org/10.1002/chem.202300829
    28. I. Kekessie et al., “Process mass intensity (PMI): A holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis,” J. Org. Chem., vol. 89, no. 7, pp. 4261–4282, 2024, doi: 10.1021/acs.joc.3c01494. DOI: https://doi.org/10.1021/acs.joc.3c01494
    29. K. Gach-Janczak, J. Drogosz-Stachowicz, A. Janecka, K. Wtorek, and M. Mirowski, “Historical perspective and current trends in anticancer drug development,” Chem. Eng. News, vol. 80, no. 23, pp. 1–18, 2002.
    30. S. M. Tawfik, M. R. A. Abdollah, M. M. Elmazar, H. A. N. El-Fawal, and A. Abdelnaser, “Effects of metformin combined with antifolates on HepG2 cell metabolism and cellular proliferation,” Front. Oncol., vol. 12, no. February, pp. 1–17, 2022, doi: 10.3389/fonc.2022.828988. DOI: https://doi.org/10.3389/fonc.2022.828988
    31. F. O. Sefrji et al., “Synthetic approaches for novel fused pyrimidine derivatives: Design, structural characterization, antiviral, antitumor, and molecular docking evaluation,” Heliyon, vol. 10, no. 24, pp. 1–23, 2024, doi: 10.1016/j.heliyon.2024.e40903. DOI: https://doi.org/10.1016/j.heliyon.2024.e40903
    32. J. Y. Yoo, Y. Choi, H. Kim, and S. B. Park, “Revisiting pyrimidine-embedded molecular frameworks to probe the unexplored chemical space for protein protein interactions,” Acc. Chem. Res., vol. 57, no. 22, pp. 3254–3265, 2024, doi: 10.1021/acs.accounts.4c00452. DOI: https://doi.org/10.1021/acs.accounts.4c00452
    33. M. W. Islam et al., “A review on pyrimidine‐based derivatives: Synthesis and their biological application,” J. Heterocycl. Chem., vol. 61, no. 7, pp. 1159–1179, Jul. 2024, doi: 10.1002/jhet.4837. DOI: https://doi.org/10.1002/jhet.4837
    34. N. Ayoub, A. Gedeon, and H. Munier-Lehmann, “A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis,” Front. Pharmacol., vol. 15, no. February, pp. 1–30, 2024, doi: 10.3389/fphar.2024.1329011. DOI: https://doi.org/10.3389/fphar.2024.1329011
    35. R. Sehrawat et al., “Dihydrofolate reductase (DHFR) inhibitors: A comprehensive review,” Curr. Med. Chem., vol. 31, no. 7, pp. 799–824, Feb. 2024, doi: 10.2174/0929867330666230310091510. DOI: https://doi.org/10.2174/0929867330666230310091510
    36. H. Shamshad, R. Bakri, and A. Z. Mirza, Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases, vol. 49, no. 7. Springer Netherlands, 2022. doi: 10.1007/s11033-022-07266-8. DOI: https://doi.org/10.1007/s11033-022-07266-8
    37. R. Rahmani et al., “FTIR, NMR and UV–Visible Spectral Investigations, Theoretical Calculations, Topological Analysis, Chemical Stablity, and Molecular Docking Study on Novel Bioactive Compound: The 5-(5-Nitro Furan-2-Ylmethylen), 3-N-(2-Methoxy Phenyl),2-N′- (2-Methoxyphenyl) Imino Thiazolidin-4-One,” Polycycl. Aromat. Compd., vol. 43, no. 5, pp. 4685–4706, 2023, doi: 10.1080/10406638.2022.2094971. DOI: https://doi.org/10.1080/10406638.2022.2094971
    38. K. B. Gangurde, V. A. Adole, and D. S. Ghotekar, “Computational study: Synthesis, spectroscopic (UV–vis, IR, NMR), antibacterial, antifungal, antioxidant, molecular docking and ADME of new (E)-5-(1-(2-(4-(2,4-dichlorophenyl)thiazol-2-yl)hydrazineylidene)ethyl)-2,4-dimethylthiazole,” Results Chem., vol. 6, no. September, pp. 1–13, 2023, doi: 10.1016/j.rechem.2023.101093. DOI: https://doi.org/10.1016/j.rechem.2023.101093
    39. C. Qian, X. Li, J. Zhang, and Y. Wang, “Small molecular inhibitors that target ATM for drug discovery: Current research and potential prospective,” J. Med. Chem., vol. 67, no. 17, pp. 14742–14767, Sep. 2024, doi: 10.1021/acs.jmedchem.4c01064. DOI: https://doi.org/10.1021/acs.jmedchem.4c01064
    40. G. M. Nitulescu et al., “The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies,” Molecules, vol. 28, no. 14, pp. 1–32, 2023, doi: 10.3390/molecules28145359. DOI: https://doi.org/10.3390/molecules28145359